View source for 20240009116. DRUG DELIVERY SYSTEM COMPRISING A NON-STEROIDAL ANTI-INFLAMMATORY (NSAID) AND A PROGESTOGENIC COMPOUND AND METHODS FOR MANUFACTURING simplified abstract (Bayer OY)

=DRUG DELIVERY SYSTEM COMPRISING A NON-STEROIDAL ANTI-INFLAMMATORY (NSAID) AND A PROGESTOGENIC COMPOUND AND METHODS FOR MANUFACTURING=


==Organization Name==

[[:Category:Bayer OY|Bayer OY]]


[[Category:Bayer OY]]

==Inventor(s)==

[[:Category:Harri Jukarainen of Kuusisto (FI)|Harri Jukarainen of Kuusisto (FI)]][[Category:Harri Jukarainen of Kuusisto (FI)]]

[[:Category:Jyrki Pihlaja of Paimio (FI)|Jyrki Pihlaja of Paimio (FI)]][[Category:Jyrki Pihlaja of Paimio (FI)]]

[[:Category:Savante Holmberg of Turku (FI)|Savante Holmberg of Turku (FI)]][[Category:Savante Holmberg of Turku (FI)]]

[[:Category:Tuula Valo of Turku (FI)|Tuula Valo of Turku (FI)]][[Category:Tuula Valo of Turku (FI)]]

[[:Category:Anu-Liisa Honka of Turku (FI)|Anu-Liisa Honka of Turku (FI)]][[Category:Anu-Liisa Honka of Turku (FI)]]

[[:Category:Jenny Hollaender of Parainen (FI)|Jenny Hollaender of Parainen (FI)]][[Category:Jenny Hollaender of Parainen (FI)]]

==DRUG DELIVERY SYSTEM COMPRISING A NON-STEROIDAL ANTI-INFLAMMATORY (NSAID) AND A PROGESTOGENIC COMPOUND AND METHODS FOR MANUFACTURING - A simplified explanation of the abstract==


This abstract first appeared for US patent application 20240009116 titled 'DRUG DELIVERY SYSTEM COMPRISING A NON-STEROIDAL ANTI-INFLAMMATORY (NSAID) AND A PROGESTOGENIC COMPOUND AND METHODS FOR MANUFACTURING

==Simplified Explanation==

The abstract of this patent application describes a method for fabricating drug-containing intrauterine systems using 3D printing technique, specifically fused deposition modelling (FDM™). The drug, indomethacin, is incorporated within the entire backbone of the medical device by preparing drug-loaded poly-caprolactone (PCL) based filaments with different drug contents (5-40 wt %).

* The patent application proposes using 3D printing, specifically FDM™, to fabricate drug-containing intrauterine systems.
* The drug-loaded filaments are made from poly-caprolactone (PCL) and indomethacin.
* Different drug contents (5-40 wt %) are used to prepare the filaments.
* The drug is incorporated within the entire backbone of the medical device.
* The purpose of this innovation is to provide a method for fabricating drug-containing intrauterine systems using 3D printing, which allows for precise drug delivery and customization.

Potential applications of this technology:
* Manufacturing drug-containing intrauterine systems with precise drug delivery capabilities.
* Customizing drug-loaded medical devices for individual patients.
* Improving the effectiveness and convenience of drug delivery in intrauterine systems.

Problems solved by this technology:
* Traditional methods of fabricating drug-containing intrauterine systems may not allow for precise drug delivery or customization.
* This technology solves the problem of limited drug incorporation within the medical device by incorporating the drug within the entire backbone.
* It also solves the problem of limited customization by using 3D printing to fabricate personalized drug-loaded devices.

Benefits of this technology:
* Precise drug delivery: The drug is incorporated within the entire backbone, allowing for controlled and targeted drug release.
* Customization: 3D printing enables the fabrication of personalized drug-loaded devices, tailored to individual patients' needs.
* Improved convenience: Drug-containing intrauterine systems can be manufactured with the desired drug content, eliminating the need for separate drug administration.


==Original Abstract Submitted==

a further object of the invention is to fabricate drug-containing t-intrauterine systems (ius) with the drug incorporated within the entire backbone of the medical device by using 3d printing technique, based on fused deposition modelling (fdm™). indomethacin was used to prepare drug-loaded poly-caprolactone (pcl)-based filaments with different drug contents 5-40 wt %, namely 5%, 15% and 30% wt %:of indomethacin.



[[Category:A61K9/00]]
[[Category:B33Y80/00]]
[[Category:B29C64/118]]
[[Category:A61K9/70]]
[[Category:A61K31/405]]
[[Category:A61K31/567]]
[[Category:A61K47/32]]
[[Category:A61K47/34]]